# Is Ultragenyx Stock a Buy After GTX-102 Flop? Analysts Point to Commercial Pipeline

> **Newsylist Open Intelligence Dossier** · First detected: 2026-09-03 16:29 UTC · Category: Business · Sources: 8 · Current Velocity: 5.66

## Intelligence Brief
"Is Ultragenyx Stock a Buy After GTX-102 Flop? Analysts Point to Commercial Pipeline" developed substantial multi-source reporting across the Business sector, tracked across 8 distinct newsrooms by Newsylist.


Key reporting was led by statnews.com, seekingalpha.com, Investing.com and GuruFocus. Coverage velocity and cross-outlet momentum were measured using Newsylist open coverage telemetry.


Synthesized from multi-source international reporting and live coverage telemetry under Newsylist open intelligence methodology.

## Verified Facts & Key Claims
### What drove coverage for Is Ultragenyx Stock a Buy After GTX-102 Flop? Analysts Point to Commercial ?
Coverage spiked when 8 independent newsrooms published 8 verified reports during this coverage cycle.

### How did Newsylist track this trend?
Newsylist monitored article arrival rates, source diversity, and cross-outlet validation in real time.

## Multi-Source Evidence Table
| Source Outlet | Headline | Published (UTC) | Verification URL |
|---|---|---|---|
| statnews.com | Ultragenyx drug to treat Angelman syndrome, a rare disease, fails late-stage trial | 2026-09-03 16:28 | [Source Link](https://news.google.com/rss/articles/CBMijgFBVV95cUxOSDJteEt5OEFKQVRJYzFlelJDclhYZHVNNFdhUGlLNW5WdndhemxBVGcxRnpzN01fUm5POHFHQmoyQ2FfWGw5Q0tWSHlKbmFlOVhCd1pScW92dF9GSG5DNDB6dDhYVjVfdHF2bGt6dHBqX3hOQ3dCeVZZU3ZHeFRrUW9ObjVfaU5FSXBRWThn?oc=5) |
| seekingalpha.com | Ultragenyx drops on Phase 3 trial failure for Angelman syndrome drug (RARE:NASDAQ) | 2026-09-03 16:28 | [Source Link](https://news.google.com/rss/articles/CBMiqgFBVV95cUxNeDdCM1VZazFHbWJWR3NBRFE5dXpJUFBMLUNsVUNPdklWbjdiaE5RSWJiVF9td2ZDZ2lIUU9ZRUZYVE9xMnVzc1JyVDFIdEc3N1hTeXF5UmdZSy1RalJDMW1uTmpJb0hUc1k3RmRnbVNXcU95MDhGTGhxMUdJRVlmeUVrakhDbEpZUW9Wd2hnNDk4c2FUa2lKT3FvOU9Cc2xmei1pRE5JM1JwUQ?oc=5) |
| Investing.com | Ultragenyx stock plunges 40% on failed Angelman trial | 2026-09-03 16:28 | [Source Link](https://news.google.com/rss/articles/CBMitAFBVV95cUxOYkdMczIzU1J1bTFHX1ppM1Jsb1dIOWI0eExmbk03RmFKdTZDM1YyWEJzUE5TTEhEZW1vM3A2WjVXamxrd0czZjA4MElLVlhWZ0RPNlpFWVFCQzVoZ2toTmotM1VNUWtTNHluVDFoZXRBZ25fYWpCYWlGSGZMN0I4Q2pRb1ZPY2ptaFBhTmJ2NWJBcWJ2QnpNZFk4bV9TS1hwcVA3R3Q0eTI2Tnd3aW1zMXI2enc?oc=5) |
| GuruFocus | RARE Maintained by Canaccord Genuity -- Price Target Lowered to $37.00 | 2026-09-03 14:38 | [Source Link](https://news.google.com/rss/articles/CBMipwFBVV95cUxQZ0FTQTBKSWFoNEZOTEFVWHNUS2YtZGRpYzM4bWlERzZtVEtfd1BxTGhYSDQybkVDZVlFQnBBVVZHOW1Oa0hKT1ZYNVl3WkJ1ei1sVVh2NW9lT0JRdjVESFg3STJaT0dqb2hocld2STFPN0xHcGZYd1UwTGN1Zmtja2RmR3Q5b2hjRnZKRWlYS0tMeWhGVm5HekZRTzJoeEV0QkJ3ZUNuMA?oc=5) |
| STAT | We’re reading about an Ultragenyx failure, RevMed for lung cancer, and more | 2026-09-03 14:38 | [Source Link](https://news.google.com/rss/articles/CBMisgFBVV95cUxPb2xDb3h3b3gzWkRHam9yV0k0THB0aWpzYUVLeU1sdGlLYy1iWXBFY3B1Zkg1cDc1aFE1LVVQeVI0WC0wZTFTQ3Y3aG9WUnpOVGx0QXNyR1RKeFJqcHpPVEdnLURqOUVfc3NVcy1GR3JTdEQ1ZUNrMlUxM3N0SEZTaTgwdW5aTmVXX3F6VWplU1hoZkVwZW9md3EydmZJcXZMdGdFdUdkQmNqbk13M1NoSHln?oc=5) |
| Yahoo Finance | Ultragenyx Shares Fall After Phase 3 Aspire Study Misses Primary Endpoint | 2026-09-03 14:38 | [Source Link](https://news.google.com/rss/articles/CBMilgFBVV95cUxQRWtvd3RUNHJWZmc5bVBIYzN5ZFlOWEY0MXd2a250QWJMYTdmT3BqUEhyWERTSXR2R19waHhibjdQYXRUOHFBek8tb0stOXZvQS1MTng5WVNIQWk0S25BOWs3SlJxV2xyMUU0WFlWSzJublZJa3oyUzVZRWQtaENYTC1RWUp6akduOVVFRHBmWDZuUFB1TVE?oc=5) |
| Fierce Biotech | Ultragenyx fails phase 3 Angelman test, plots ‘significant expense reductions’ | 2026-09-03 14:38 | [Source Link](https://news.google.com/rss/articles/CBMiswFBVV95cUxQTmJTbDZqWVJ3S1lRalJvY29La3N4SkptMVZCQlN2Zm5ubkxhbk5GNml2aDhqTWp6SGJDZlE4Qi0zaURCSmRGRjNjMWMtZzZpSjdRMkh4Z05NU0puMmdvQmlISmlZaUkzYkxYRnJGNzNQTWxqSnk5RjZ0bVRiZEFKQjNFTDZidHlsenFKQUUzeDg2TU5iRERLSFlGVE84MnFoWDFQdWlkNEpkczZ6QXhMa0xJbw?oc=5) |
| barrons.com | Is Ultragenyx Stock a Buy After GTX-102 Flop? Analysts Point to Commercial Pipeline | 2026-09-03 14:38 | [Source Link](https://news.google.com/rss/articles/CBMilAFBVV95cUxOSFlIY1hKMlExSDlIZFdGTFVPRkI4Q1ltd256YXF1My1nSkptOEJmbkpSd3FEOXJhYWJoUURrYjl0UlQyaFlHT3ZfR1hLbnlleTgyNmZzVWJpRGRYTm1RbHFXSGMtQnlvc0RHdGxUTzVQU0RvdEpCT1VMZnFuN0JqejY4bEFkVG1xZThoaG83WmswaVFW?oc=5) |

---
*Canonical Source: https://www.newsylist.com/trend/2026-09-03/is-ultragenyx-stock-a-buy-after-gtx-102-flop-analysts-point-to-commercial*
*Synthesized by Newsylist Open Intelligence Engine under E-E-A-T journalistic standards.*